[ALKS] FDA Approved.
stockcharts.com
Alkermes and Cephalon Receive FDA Approval of Vivitrol(TM) for the Treatment of Alcohol Dependence
Thursday April 13, 3:50 pm ET
First, Once-Monthly Injectable Medication Provides New Treatment Option
Companies to Host Conference Call at 4:30 p.m. EDT
CAMBRIDGE, Mass. and FRAZER, Pa.--(BUSINESS WIRE)--April 13, 2006--Alkermes, Inc., (Nasdaq: ALKS - News) and Cephalon, Inc., (Nasdaq: CEPH - News) today announced that the U.S. Food and Drug Administration (FDA) has approved VIVITROL(TM) (naltrexone for extended-release injectable suspension) for the treatment of alcohol dependence. VIVITROL, the first and only once-monthly injectable medication for alcohol dependence, is indicated for alcohol dependent patients who are able to abstain from drinking in an outpatient setting and are not actively drinking when initiating treatment. Treatment with VIVITROL should be used in combination with psychosocial support, such as counseling or group therapy.
biz.yahoo.com |
